IP Library Granted Patent US 7,229,824
Granted Patent B2
US 7,229,824 · App. 10/621,741 · Granted Jun 12, 2007

Ribonucleases and methods of making them recombinantly

Assignee: Alfacell Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,229,824
App. No.
10/621,741
Granted
Jun 12, 2007
Kind
B2
Abstract

Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.

Claims (3)

1. A vector containing the DNA of SEQ ID NO: 2 encoding the ribonuclease of SEQ ID NO: 1.

2. A pET11d plasmid vector containing the DNA of SEQ ID NO: 2 encoding the ribonuclease of SEQ ID NO: 1.

3. A pET22b plasmid vector containing the DNA of SEQ ID NO: 2 encoding the ribonuclease of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2020
From: TAMIR BIOTECHNOLOGY, INC.
To: ORGENESIS INC.
Reel/Frame 052892/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2004
From: SAXENA, SHAILENDRA K.
To: ALFACELL CORPORATION
Reel/Frame 014385/0201 →
Continuity (1)
Related Publication 20050014161A1 · Jan 20, 2005